Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy
International Journal of Urology · 2025
DOI: 10.1111/iju.70065 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Yoshie Mita und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nivolumab, Kidney Neoplasms, Ipilimumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Introduction and Objectives This study assessed the prognostic value of maximal evaluable lesion size (MLS) in predicting the efficacy and outcomes of nivolumab plus ipilimumab (NIVO+IPI) therapy for metastatic renal cell carcinoma (mRCC).
Methods
We retrospectively analyzed 99 mRCC patients treated with NIVO + IPI. Patients were divided into larger‐MLS (≥ 35 mm) and smaller‐MLS (< 35 mm) groups based on the median MLS. Objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS) were compared, and predictive factors for PFS and OS were identified.
Results
The median follow‐up period was 29.5 months. In the larger‐MLS group (50 patients), the number of patients who did not undergo cytoreductive nephrectomy, as well as the number of patients in whom the kidney, lymph node, and lung were identified as an organ of MLS origin, was significantly higher compared to the smaller‐MLS group. ORR was 40% in the larger‐MLS group and 32.7% in the smaller‐MLS group ( p = 0.4315). However, PFS and OS were significantly worse in the larger‐MLS group ( p = 0.0016 and p = 0.0002, respectively). Multivariate analysis identified Karnofsky performance status (KPS) < 80%, non‐clear cell histology, and larger MLS as independent predictors of worse PFS and OS. A prognostic model integrating MLS, KPS, and histology stratified patients effectively, with ≥ 2 risk factors predicting significantly worse OS ( p < 0.0001).
Conclusions
MLS is a key prognostic factor in mRCC patients treated with NIVO+IPI. A risk model incorporating MLS, KPS, and histology can aid in patient stratification and treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Takuto Hara, Hideto Ueki, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Tomoaki Terakawa
Zitieren
APA
Mita, Y., Teishima, J., Hara, T., Ueki, H., Wakita, N., Okamura, Y., Suzuki, K., Bando, Y., Terakawa, T., Chiba, K., & Miyake, H. (2025). Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy. International Journal of Urology. https://doi.org/10.1111/iju.70065
Vancouver
Mita Y, Teishima J, Hara T, Ueki H, Wakita N, Okamura Y, et al. Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy. International Journal of Urology. 2025. doi:10.1111/iju.70065
BibTeX
@article{Mita2025,
author = {Mita, Yoshie and Teishima, Jun and Hara, Takuto and Ueki, Hideto and Wakita, Naoto and Okamura, Yasuyoshi and Suzuki, Kotaro and Bando, Yukari and Terakawa, Tomoaki and Chiba, Koji and Miyake, Hideaki},
title = {Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70065}
}
EUVIMED